Evidence map›Paper›PMID 31945705›Full record

ReviewCurrent opinion in chemical biology2020

Exploiting azide-alkyne click chemistry in the synthesis, tracking and targeting of platinum anticancer complexes.

Nicola J Farrer, Darren M Griffith

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Novel Platinum(II) Tetrazine Complex Capable of Live-Cell IEDDA Reaction.Chembiochem : a European journal of chemical biology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nicola J FarrerChemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.
Darren M GriffithDepartment of Chemistry, RCSI, 123 St. Stephens Green, Dublin 2, Ireland; SSPC, Synthesis and Solid State Pharmaceutical Centre, Ireland. Electronic address: dgriffith@rcsi.com.

Funding

Cancer Research UK C5255/A18085Wellcome Trust 201406/Z/16/Z
6 · The paper itself

Abstract

Click chemistry is fundamentally important to medicinal chemistry and chemical biology. It represents a powerful and versatile tool, which can be exploited to develop novel Pt-based anticancer drugs and to better understand the biological effects of Pt-based anticancer drugs at a cellular level. Innovative azide-alkyne cycloaddition-based approaches are being used to functionalise Pt-based complexes with biomolecules to enhance tumour targeting. Valuable information in relation to the mechanisms of action and resistance of Pt-based drugs is also being revealed through click-based detection, isolation and tracking of Pt drug surrogates in biological and cellular environments. Although less well-explored, inorganic Pt-click reactions enable synthesis of novel (potentially multimetallic) Pt complexes and provide plausible routes to introduce functional groups and monitoring Pt-azido drug localisation.

Indexed as

AlkynesAntineoplastic AgentsAzidesCellular MicroenvironmentClick ChemistryCopperCycloaddition ReactionDrug DevelopmentDrug ResistanceFluorescent DyesGoldHumansLigandsMolecular StructureOrganometallic CompoundsPlatinumAlkynesAntineoplastic AgentsAzidesCopperFluorescent DyesGoldLigandsOrganometallic CompoundsPlatinumTriazolesAlkyneAnalyseAnticancerAzideCuAACCycloadditionFunctionaliseiClickPlatinumSPAACSynthesisTargetTrackTriazole

Identifiers

PMID31945705
PMCPMC7254056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.